EUCTR2015-001030-16-Outside-EU/EEA进行中（未招募）不适用
A Phase 2b, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of the 3rd Dose of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adolescents in the U.S.
ovartis Vaccines and Diagnostics Inc.0 个研究点目标入组 305 人开始时间: 2016年4月28日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 305
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Adolescents who completed V102_16 study and received the study vaccines as assigned in the protocol (either two doses of the MenABCWY or one dose each of MenACWY and Placebo).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 291
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 14
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Serious, acute, or chronic illnesses. Previous or suspected disease caused by N. meningitidis.
- •2) History of any meningococcal vaccine administration other than vaccination given in the parent V102_16 protocol.
研究者
相似试验
进行中（未招募）
不适用
Immune Response Induced by a Trivalent Group B strep. vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings.Prophylaxis against Group B Streptococcus infection.EUCTR2010-020840-36-Outside-EU/EEAovartis Vaccines and Diagnostics100
进行中（未招募）
1 期
Testing a vaccine in pregnant woman to protect their newborn babies from blood poisoning caused by a bacteriumInvasive group B streptococcus diseaseMedDRA version: 13.1Level: PTClassification code 10053588Term: Group B streptococcus neonatal sepsisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-020840-36-BEovartis Vaccines and Diagnostics GmbH100
进行中（未招募）
不适用
A Phase II, Randomized, Observer Blind, Multi-Center, Active Controlled Study toEvaluate the Safety and Immunogenicity of Chiron Meningococcal ACWY ConjugateVaccine in Healthy Children Aged 12-59 MonthsEUCTR2004-001896-21-FIChiron S.r.l.600
进行中（未招募）
1 期
Study conducted in healthy adolescents to evaluate safety and antibody response after the administration of different schedules of a vaccine produced by Novartis Vaccines and Diagnostics compared to Novartis Meningococcal group B vaccineand and directed against Meningococcal serogroup A, B, C, Y and W strains.The current study is designed to assess immunological non-inferiority of the MenABCWY vaccine, administered according to 0, 2 month schedule to healthy adolescents 10 to 18 years of age, to those of the licensed rMenB+OMV vaccine (Bexsero™) in terms of hSBA GMTs at one month after the second vaccination.MedDRA version: 19.0Level: PTClassification code 10027202Term: Meningitis bacterialSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-002451-15-PLGlaxoSmithKline Biologicals SA1,050
进行中（未招募）
1 期
Study conducted in healthy adolescents to evaluate safety and antibody response after the administration of different schedules of a vaccine produced by GSK Vaccines and Diagnostics compared to GSK Meningococcal group B vaccineand and directed against Meningococcal serogroup A, B, C, Y and W strains.EUCTR2013-002451-15-FIGlaxoSmithKline Biologicals SA1,050